• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PXSQuarterly Report to Shareholders25/01/11
PXSEU Bronchitol Marketing Application UpdatePRICE SENSITIVE25/01/11
PXSAppendix 3B - Grant of Employee Options25/01/11
PXSQuarterly Investor Report and Conference Call24/01/11
PXSDisclosure notice under section 708A(5) of Corporations Act19/01/11
PXSAppendix 3B19/01/11
PXSBecoming a substantial holder14/01/11
PXSAppendix 3B - Exercise of Employee Options12/01/11
PXSAppendix 3B - Exercise of Employee Options21/12/10
PXSShare Trading Policy21/12/10
PXSBronchitol EU Marketing Authorisation UpdatePRICE SENSITIVE20/12/10
PXSExtended Benefit with Bronchitol in Second PhaseIII CF TrialPRICE SENSITIVE16/12/10
PXSPharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol15/12/10
PXSCeasing to be a substantial holder14/12/10
PXSBronchitol Recommended for Approval by Australian Advisory CPRICE SENSITIVE13/12/10
PXSPhase II Trial of ASM8 in Asthma CommencesPRICE SENSITIVE07/12/10
PXSAppendix 3B - Exercise of Employee Options30/11/10
PXSAppendix 3B - Exercise of Employee Options25/11/10
PXSChange of Director's Interest Notice25/11/10
PXSAppendix 3B Exercise of Employee Options16/11/10
PXSAppendix 3B - Grant of Employee Performance Rights15/11/10
PXSUpdated Investor Presentation09/11/10
PXSAppendix 3B - Exercise of Employee Options08/11/10
PXSAPpendix 3B - Exercise of Employee Options02/11/10
PXSAppendix 3B - Exercise of Employee Options28/10/10
PXSAppendix 3B - Exercise of Employee Options22/10/10
PXSPharmaxis Announces Positive Combined Phase 3 CF ResultsPRICE SENSITIVE22/10/10
PXSBecoming a substantial holder21/10/10
PXSChange of Director's Interest Notice20/10/10
PXSResults of Meeting20/10/10
PXSAppendix 3B - Option Issue20/10/10
PXSCEO Presentation to 2010 AGM20/10/10
PXSChairman's Address to 2010 AGM20/10/10
PXSPharmaxis CEO Resumes Office20/10/10
PXSAppendix 4C - quarterlyPRICE SENSITIVE13/10/10
PXSQuarterly Report to Shareholders13/10/10
PXSQuarterly Investor Conference Call12/10/10
PXSBecoming a substantial holder12/10/10
PXSUS FDA APPROVES ARIDOLPRICE SENSITIVE06/10/10
PXSAppendix 3B - grant of employee equity27/09/10
PXSNotice of 2010 Annual General Meeting/Proxy Form10/09/10
PXSPharmaxis 2010 Annual Review10/09/10
PXSStatutory Annual Report10/09/10
PXSProposed issue of options to CEO08/09/10
PXSAppendix 3B - annual grant of employee options08/09/10
PXSAgreement for European Marketing of BronchitolPRICE SENSITIVE31/08/10
PXSExercise of Employee Options27/07/10
PXSQuarterly Report to Shareholders - June 201021/07/10
PXSAppendix 4C - quarterlyPRICE SENSITIVE21/07/10
PXSQuarterly Investor Conference Call Details20/07/10
PXSUpdate on Pharmaxis CEO08/07/10
PXSCeasing to be a substantial holder25/06/10
PXSUpdated Investor Presentation24/06/10
PXSResults for Second Phase 3 Trial of Bronchitol in CFPRICE SENSITIVE22/06/10
PXSInvestor Conference Call - Clinical Trial Results22/06/10
PXSTrading HaltPRICE SENSITIVE21/06/10
PXSPharmaxis CEO18/06/10
PXSExercise of Employee Options31/05/10
PXSSustained Benefit Following 18 Month Bronchitol TreatmentPRICE SENSITIVE17/05/10
PXSAppendix 3B - Exercise of Employee Options30/04/10
PXSPharmaxis resubmission for Aridol US marketing application27/04/10
PXSAppendix 3B - Exercise of Employee Options23/04/10
PXSChange in substantial holding22/04/10
PXSAppendix 4C - quarterly March 2010PRICE SENSITIVE14/04/10
PXSMarch 2010 Quarterly Report to Shareholders14/04/10
PXSPharmaxis Announces Milestone in Phase 3 Trial for CFPRICE SENSITIVE14/04/10
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL12/04/10
PXSAppendix 3B - Exercise of Employee Options23/03/10
PXSDisclosure notice under section 708A(5)(e)15/03/10
PXSAppendix 3B - Topigen Milestone Payment15/03/10
PXSPharmaxis Completes Phase II Clinical Study with ASM8PRICE SENSITIVE11/03/10
PXSChange in substantial holding10/03/10
PXSInvestor Presentation02/03/10
PXSDisclosure notice under section 708A(5) of Corporations Act09/02/10
PXSAppendix 3B - Topigen Acquisition09/02/10
PXSPharmaxis completes acquisition of Topigen Pharmaceuticals09/02/10
PXSPharmaxis completes clinical trial with PXS25PRICE SENSITIVE09/02/10
PXSAppendix 3B - Exercise of Employee Options05/02/10
PXSHalf Yearly Report and AccountsPRICE SENSITIVE05/02/10
PXSUpdated Investor Presentation28/01/10
PXSAppendix 4C - Quarterly Cash FlowPRICE SENSITIVE27/01/10
PXSDecember 2009 Quarterly Report to Shareholders27/01/10
PXSInvestor Conference Call22/01/10
PXSPharmaxis to acquire Canadian company TOPIGEN PharmaceuticalPRICE SENSITIVE12/01/10
PXSPharmaxis receives response letter from the FDA on AridolPRICE SENSITIVE29/12/09
PXSPharmaxis lodges TGA application to market Bronchitol for CFPRICE SENSITIVE17/12/09
PXSExercise of Employee Options09/12/09
PXSChange of Director's Interest Notice08/12/09
PXSChange in substantial holding03/12/09
PXSPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOLPRICE SENSITIVE02/12/09
PXSChange of Director's Interest Notice - Appendix 3Y26/11/09
PXSAppendix 3B - Exercise of Employee Options26/11/09
PXSFDA Advisory Committee Recommends Approval of Aridol23/11/09
PXSPharmaxis Applies to Market Bronchitol for CF in EuropePRICE SENSITIVE29/10/09
PXSAppendix 3B - Exercise of Employee Options27/10/09
PXSCommencement of Bronchiectasis Study and Aligning StrategyPRICE SENSITIVE23/10/09
PXSAppendix 3Y - Mr Richard van den Broek22/10/09
PXSAppendix 3Y - Dr Alan Robertson22/10/09
PXSAppendix 3B22/10/09
PXSFinal Director's Interest Notice22/10/09
PXSQuarterly Report to Shareholders
25/01/11
PXSEU Bronchitol Marketing Application Update
25/01/11PRICE SENSITIVE
PXSAppendix 3B - Grant of Employee Options
25/01/11
PXSQuarterly Investor Report and Conference Call
24/01/11
PXSDisclosure notice under section 708A(5) of Corporations Act
19/01/11
PXSAppendix 3B
19/01/11
PXSBecoming a substantial holder
14/01/11
PXSAppendix 3B - Exercise of Employee Options
12/01/11
PXSAppendix 3B - Exercise of Employee Options
21/12/10
PXSShare Trading Policy
21/12/10
PXSBronchitol EU Marketing Authorisation Update
20/12/10PRICE SENSITIVE
PXSExtended Benefit with Bronchitol in Second PhaseIII CF Trial
16/12/10PRICE SENSITIVE
PXSPharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol
15/12/10
PXSCeasing to be a substantial holder
14/12/10
PXSBronchitol Recommended for Approval by Australian Advisory C
13/12/10PRICE SENSITIVE
PXSPhase II Trial of ASM8 in Asthma Commences
07/12/10PRICE SENSITIVE
PXSAppendix 3B - Exercise of Employee Options
30/11/10
PXSAppendix 3B - Exercise of Employee Options
25/11/10
PXSChange of Director's Interest Notice
25/11/10
PXSAppendix 3B Exercise of Employee Options
16/11/10
PXSAppendix 3B - Grant of Employee Performance Rights
15/11/10
PXSUpdated Investor Presentation
09/11/10
PXSAppendix 3B - Exercise of Employee Options
08/11/10
PXSAPpendix 3B - Exercise of Employee Options
02/11/10
PXSAppendix 3B - Exercise of Employee Options
28/10/10
PXSAppendix 3B - Exercise of Employee Options
22/10/10
PXSPharmaxis Announces Positive Combined Phase 3 CF Results
22/10/10PRICE SENSITIVE
PXSBecoming a substantial holder
21/10/10
PXSChange of Director's Interest Notice
20/10/10
PXSResults of Meeting
20/10/10
PXSAppendix 3B - Option Issue
20/10/10
PXSCEO Presentation to 2010 AGM
20/10/10
PXSChairman's Address to 2010 AGM
20/10/10
PXSPharmaxis CEO Resumes Office
20/10/10
PXSAppendix 4C - quarterly
13/10/10PRICE SENSITIVE
PXSQuarterly Report to Shareholders
13/10/10
PXSQuarterly Investor Conference Call
12/10/10
PXSBecoming a substantial holder
12/10/10
PXSUS FDA APPROVES ARIDOL
06/10/10PRICE SENSITIVE
PXSAppendix 3B - grant of employee equity
27/09/10
PXSNotice of 2010 Annual General Meeting/Proxy Form
10/09/10
PXSPharmaxis 2010 Annual Review
10/09/10
PXSStatutory Annual Report
10/09/10
PXSProposed issue of options to CEO
08/09/10
PXSAppendix 3B - annual grant of employee options
08/09/10
PXSAgreement for European Marketing of Bronchitol
31/08/10PRICE SENSITIVE
PXSExercise of Employee Options
27/07/10
PXSQuarterly Report to Shareholders - June 2010
21/07/10
PXSAppendix 4C - quarterly
21/07/10PRICE SENSITIVE
PXSQuarterly Investor Conference Call Details
20/07/10
PXSUpdate on Pharmaxis CEO
08/07/10
PXSCeasing to be a substantial holder
25/06/10
PXSUpdated Investor Presentation
24/06/10
PXSResults for Second Phase 3 Trial of Bronchitol in CF
22/06/10PRICE SENSITIVE
PXSInvestor Conference Call - Clinical Trial Results
22/06/10
PXSTrading Halt
21/06/10PRICE SENSITIVE
PXSPharmaxis CEO
18/06/10
PXSExercise of Employee Options
31/05/10
PXSSustained Benefit Following 18 Month Bronchitol Treatment
17/05/10PRICE SENSITIVE
PXSAppendix 3B - Exercise of Employee Options
30/04/10
PXSPharmaxis resubmission for Aridol US marketing application
27/04/10
PXSAppendix 3B - Exercise of Employee Options
23/04/10
PXSChange in substantial holding
22/04/10
PXSAppendix 4C - quarterly March 2010
14/04/10PRICE SENSITIVE
PXSMarch 2010 Quarterly Report to Shareholders
14/04/10
PXSPharmaxis Announces Milestone in Phase 3 Trial for CF
14/04/10PRICE SENSITIVE
PXSPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
12/04/10
PXSAppendix 3B - Exercise of Employee Options
23/03/10
PXSDisclosure notice under section 708A(5)(e)
15/03/10
PXSAppendix 3B - Topigen Milestone Payment
15/03/10
PXSPharmaxis Completes Phase II Clinical Study with ASM8
11/03/10PRICE SENSITIVE
PXSChange in substantial holding
10/03/10
PXSInvestor Presentation
02/03/10
PXSDisclosure notice under section 708A(5) of Corporations Act
09/02/10
PXSAppendix 3B - Topigen Acquisition
09/02/10
PXSPharmaxis completes acquisition of Topigen Pharmaceuticals
09/02/10
PXSPharmaxis completes clinical trial with PXS25
09/02/10PRICE SENSITIVE
PXSAppendix 3B - Exercise of Employee Options
05/02/10
PXSHalf Yearly Report and Accounts
05/02/10PRICE SENSITIVE
PXSUpdated Investor Presentation
28/01/10
PXSAppendix 4C - Quarterly Cash Flow
27/01/10PRICE SENSITIVE
PXSDecember 2009 Quarterly Report to Shareholders
27/01/10
PXSInvestor Conference Call
22/01/10
PXSPharmaxis to acquire Canadian company TOPIGEN Pharmaceutical
12/01/10PRICE SENSITIVE
PXSPharmaxis receives response letter from the FDA on Aridol
29/12/09PRICE SENSITIVE
PXSPharmaxis lodges TGA application to market Bronchitol for CF
17/12/09PRICE SENSITIVE
PXSExercise of Employee Options
09/12/09
PXSChange of Director's Interest Notice
08/12/09
PXSChange in substantial holding
03/12/09
PXSPHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL
02/12/09PRICE SENSITIVE
PXSChange of Director's Interest Notice - Appendix 3Y
26/11/09
PXSAppendix 3B - Exercise of Employee Options
26/11/09
PXSFDA Advisory Committee Recommends Approval of Aridol
23/11/09
PXSPharmaxis Applies to Market Bronchitol for CF in Europe
29/10/09PRICE SENSITIVE
PXSAppendix 3B - Exercise of Employee Options
27/10/09
PXSCommencement of Bronchiectasis Study and Aligning Strategy
23/10/09PRICE SENSITIVE
PXSAppendix 3Y - Mr Richard van den Broek
22/10/09
PXSAppendix 3Y - Dr Alan Robertson
22/10/09
PXSAppendix 3B
22/10/09
PXSFinal Director's Interest Notice
22/10/09
refresh Created with Sketch. REFRESH
 

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.